Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
STAM mice develop NASH-derived hepatocarcinoma
Last year, the following article was even published in Nature Reviews Gastroenterology & Hepatology. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention –What is liver cancer? Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma…
2025.02.02
Combination Therapies for NASH
It is now accepted that many factors are involved in exacerbating the NASH pathophysiology such as lipotoxicity, oxidative stress, microbiome and immune cell mechanisms. To date, numerous molecules with different mechanisms of action have been developed to treat NASH, although reported efficacy to date has been limited. Considering the complexity of the pathophysiology, many companies…
2025.02.02
Pre-clinical studies for NASH: CDAHFD mice model
Today, we would like to give you a brief introduction to the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced NASH model. The CDAHFD model is a non-obese NASH model that is induced by feeding the test animals a choline-deficient, L-amino acid-defined, high-fat diet. The model reproduces NASH phenotypes such as marked steatosis, immune cell infiltration and…
2025.02.02
Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NASH-HCC. This model also boasts a high clinical correlation and has been featured in over 70 papers and more than 80 presentation. What is more, over 10 of our clients that have used this model have…
2025.02.02
Drug Efficacy Studies in Custom Model_ Muscular Dystrophy Mouse Model
In order to meet the diversifying needs of our clients, we often use our years of expertise conducting preclinical animal models to help our clients establish custom models that are not currently on our lineup. This process involves evaluating the potential efficacy of a model based on the available literature and then running the model…
2025.02.02
Preclinical studies for COPD research: PPE model
We would like to share with you about our Porcine pancreatic elastase (PPE)-induced pulmonary emphysema model, known as a disease model for chronic obstructive pulmonary disease (COPD). This model develops pulmonary emphysema due to elastin degradation in the lung tissue and consequent immune cell infiltration caused by elastin fragments. Here at SMC, we use a Microsprayer…
2025.02.02
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. Nonalcoholic fatty liver…
2025.02.02
New drugs for chronic kidney disease are desired
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population? Last year, the following article was published in Nature Reviews Nephrology (Soler et al., Nature Reviews Nephrology., 2021). The COVID-19 pandemic: progress in nephrology The…
2025.02.02
Clinically correlated gut dysfunction in liver disease model
We would like to share with you our presentation from the 5th Korea Digestive Disease Week (KDDW 2021) (November 18 to 20, 2021). ABS-0579| Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet In this presentation, the increased intestinal permeability or…
2025.02.02
Combination study with our proprietary NASH-HCC model
We would like to introduce the combination study using NASH model mice. Combination study in NASH These days, a lot of pharmaceutical companies are trying to conduct combination studies for NASH. Since NASH shows a variety of symptoms like steatosis, inflammation and fibrosis, pharmaceutical companies expect synergistic effect through administration of drug candidates which…
We can help you advance your research.